Zika virus vaccines

US10898566B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Barney Graham · Rockville, US
• Theodore Pierson · Poolesville, US
• Kimberly Dowd · Columbia, US
• John Mascola · Rockville, US
• Wing-Pui Kong · Germantown, US
• Sung-Youl Ko · Rockville, US
• Eun Sung Yang · Rockville, US
• Wei Shi · 安丰镇, CN
• Lingshu Wang · North Potomac, US
• Christina DEMASO · Rockville, US
• Rebecca S. Pelc · Morrisville, US
• Adrian Creanga · Bethesda, US
• Julie Ledgerwood · Bethesda, US
• Leda R. Castilho · Rio de Janeiro, BR

Key dates

• Filing date: Jul 28, 2017
• Grant date: Jan 26, 2021
• Expiry date: Jul 28, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a vaccine for Zika virus, the vaccine comprising Zika virus membrane and envelope proteins. More specifically, the vaccine comprises nucleic acid molecules encoding modified Zika virus membrane and/or envelope proteins. When introduced into a cell, the encoded proteins are produced, which results in the production of a virus-like particle capable of eliciting an immune response against Zika virus.